Business Context and Reporting Period
This Form 8-K is a current report filed by ADVENTRX Pharmaceuticals, Inc. (not Savara Inc.) on April 11, 2008. The filing discloses the departure of a senior executive and the terms of his separation and subsequent consulting arrangement.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation and separation costs.
- Separation Payment (Salary): $125,000 (equivalent to six months of base salary).
- Benefit Continuation Payment: $20,997 (covers health, welfare, and retirement benefits for six months).
- Stock Option Acceleration: 31,250 previously unvested shares were accelerated to vested status.
- Total Vested Options Post-Acceleration: 109,375 shares (exercise price: $2.57/share).
- Consulting Fee Cap: Maximum liability of $20,000 for future consulting services.
Material Changes
The primary material change is the departure of Gregory P. Hanson, who served as Chief Financial Officer, Treasurer, and Senior Vice President. His departure was effective April 2, 2008. The company has incurred immediate liabilities for the separation package and established a new contractual obligation for potential consulting services.
Outlook, Risks, and Unusual Items
Management Commentary and Arrangements:
- Payment Schedule: The salary and benefit payments will be made in substantially equal installments over the next 13 pay periods.
- Consulting Agreement: Mr. Hanson will provide services on an as-needed basis. Rates are $250/hour for the first 10 hours per month and $150/hour thereafter. The agreement cannot be terminated by Mr. Hanson prior to December 31, 2008, except for non-payment.
- Confidentiality: Mr. Hanson is required to maintain confidentiality regarding proprietary information.
Risks: The filing notes that the description of agreements is qualified by reference to the full exhibits. There is no specific discussion of operational risks or contingencies beyond the standard terms of the separation.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise deadline (September 29, 2008) for the 109,375 vested shares.
- Confirm the impact of the $145,997 total separation cost on the company's current cash position.
- Review the full text of Exhibit 10.1 (Separation Letter) and Exhibit 10.2 (Consulting Agreement) for non-disclosure or non-compete clauses not summarized here.
- Monitor future filings for the appointment of a new Chief Financial Officer.